爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

orion corporation - estsitalopraam - õhukese polümeerikattega tablett - 20mg 50tk; 20mg 14tk; 20mg 500tk; 20mg 28tk; 20mg 100tk; 20mg 30tk; 20mg 84tk; 20mg 10tk; 20mg 49tk; 20mg 7tk; 20mg 200tk; 20mg 90tk; 20mg 98tk; 20mg 15tk; 20mg 56tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

orion corporation - estsitalopraam - õhukese polümeerikattega tablett - 5mg 20tk; 5mg 28tk; 5mg 84tk; 5mg 10tk; 5mg 90tk; 5mg 56tk; 5mg 200tk; 5mg 7tk; 5mg 60tk; 5mg 100tk; 5mg 14tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

orion corporation - estsitalopraam - õhukese polümeerikattega tablett - 15mg 56tk; 15mg 90tk; 15mg 30tk; 15mg 84tk; 15mg 7tk; 15mg 15tk; 15mg 20tk; 15mg 60tk; 15mg 50tk; 15mg 49tk; 15mg 28tk; 15mg 98tk; 15mg 500tk; 15mg 10tk; 15mg 200tk; 15mg 14tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

orion corporation - mirtasapiin - suus dispergeeruv tablett - 30mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

orion corporation - mirtasapiin - suus dispergeeruv tablett - 45mg 90tk; 45mg 30tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

orion corporation - nebivolool - tablett - 5mg 30tk; 5mg 100tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

爱沙尼亚 - 爱沙尼亚文 - Adama

adama - emulsioonikontsentraat - propakvisafop - herbitsiidid

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

gedeon richter plc. - follitropiin alfa - anovulatsioon - suguhormoonid ja genitaalsüsteemi, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. kliinilistes uuringutes on nendel patsientidel olid määratletud on endogeensed seerumi lh tase < 1. 2 rÜ / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

teva pharma b.v. - nifedipiin - toimeainet prolongeeritult vabastav tablett - 10mg 100tk; 10mg 30tk